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ABSTRACT
COPD has a profound impact on daily life, yet remains underdiagnosed and undertreated.
We set out to develop a brief, reliable, self-scored questionnaire to identify individuals likely
to have COPD. COPD-PSTM development began with a list of concepts identiﬁed for inclusion
using expert opinion from a clinician working group comprised of pulmonologists (n = 5)
and primary care clinicians (n = 5). A national survey of 697 patients was conducted at 12
practitioner sites. Logistic regression identiﬁed items discriminating between patients with
and without ﬁxed airﬂow obstruction (AO, postbronchodilator FEV1/FVC < 70%). ROC analyses
evaluated screening accuracy, compared scoring options, and assessed concurrent validity.
Convergent and discriminant validity were assessed via COPD-PS and SF-12v2 score correla-
tions. For known-groups validation, COPD-PS differences between clinical groups were tested.
Test-retest reliability was evaluated in a 20% sample. Of 697 patients surveyed, 295 patients met
expert review criteria for spirometry performance; 38% of these (n = 113) had results indicating
AO. Five items positively predicted AO (p < 0.0001): breathlessness, productive cough,
activity limitation, smoking history, and age. COPD-PS scores accurately classiﬁed AO status
(area under ROC curve = 0.81) and reliable (r = 0.91). Patients with spirometry indicative of
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COPD: Journal of Chronic Obstructive Pulmonary Disease April 2008 85AO scored signiﬁcantly higher (6.8, SD = 1.9; p < 0.0001) than patients without AO (4.0, SD =
2.3). Higher scores were associated with more severe AO, bronchodilator use, and overnight
hospitalization for breathing problems. With the prevalence of COPD in the studied cohort, a
score on the COPD-PS of greater than ﬁve was associated with a positive predictive value of
56.8% and negative predictive value of 86.4%. The COPD-PS accurately classiﬁed physician-
reported COPD (AUC = 0.89). The COPD-PS is a brief, accurate questionnaire that can identify
individuals likely to have COPD.
INTRODUCTION
Chronicobstructivepulmonarydisease(COPD)isacommon
disease with a profound impact on a patient’s functioning and is
underdiagnosed (1). A major objective of the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) is to increase
awareness among healthcare providers and the general public
of the signiﬁcance of COPD symptoms (2). Despite the exis-
tence of evidence-based diagnostic and treatment guidelines,
many patients with COPD continue to be undiagnosed or mis-
diagnosed. COPD may remain undiagnosed for several reasons.
Patientsmaynotvisitaphysicianbecausetheyhavebecomeac-
customed to symptoms, may be concerned that their respiratory
symptoms are self-inﬂicted, or are unsure whether COPD can
be treated (3, 4). Additionally, spirometry is underutilized (5–7)
and may be difﬁcult to interpret by some healthcare providers
(8, 9). Furthermore, asthma and COPD may be confused as they
can both exhibit ﬁxed airﬂow obstruction (AO) (10).
COPD screening that focuses only on patients meeting a
limited set of characteristics, such as older smokers, may fail
to detect COPD among individuals in the general population
(e.g., younger adults with early disease) (11) or those having
another etiology (e.g., occupational exposure). Similarly, iden-
tifyingonlyindividualswhoarecurrentsmokersmaymissthose
with COPD symptoms who have already quit smoking (11).
Hence, there is a need for a simple method to help identify
persons who might have COPD. A simple, self-administered,
self-scored tool to screen individuals for the disease may lead to
increased awareness, earlier symptom recognition, and the use
of spirometry for accurate diagnosis. Dissemination of such a
tool in the general population might encourage individuals to
discuss their respiratory symptoms with a healthcare provider.
This tool could also assist physicians in identifying those in-
dividuals who would need spirometric assessment. Although
several investigators have developed surveys for describing the
impact of COPD, measuring the outcomes of treatment, or as-
sessing disease severity, there are few tools designed to identify
patients with COPD in a nonclinical setting (12).
We developed a simple, self-administered screening tool for
the identiﬁcation of patients with possible COPD in the general
population. The COPD Population ScreenerTM(COPD-PSTM;
QualityMetric Incorporated, Lincoln, Rhode Island, USA) is a
5-item questionnaire, designed to meet the following criteria:
(1) a high correct classiﬁcation rate for AO diagnosis while re-
taining a good trade-off between sensitivity and speciﬁcity; (2)
self-scored,brief,andsimpletocomplete;and(3)demonstrated
adequate levels of reliability and preliminary evidence for va-
lidity. Of particular interest was the development of a tool ap-
propriate for the general population rather than patients already
seeking treatment for respiratory difﬁculties.
MATERIALS AND METHODS
Working Group and Survey Development: A clinician
working group comprised of 5 pulmonary specialists, 4 pri-
mary care physicians, and 1 respiratory therapy professor was
assembled to assist in the development of the COPD-PS ques-
tionnaire. The working group guided development of speciﬁc
survey-question content, participated in designing a clinical de-
velopment and validation study, and assisted in the evaluation
of the study results.
Based on clinical experience, this working group ﬁrst iden-
tiﬁed 7 conceptual domains relevant to the detection of COPD
andeasilyidentiﬁedbypatients.Adevelopmentsurveyincluded
items that measured the conceptual domains in terms of pres-
ence,frequency,duration,orquality.Anabbreviateddescription
oftheseitemsiscontainedinTable1,whileacompletelistofthe
items is enumerated in the Appendix. Additionally, a 12-item,
short-form, general health-status assessment (SF-12
  Rv2 Health
SurveyTM [QualityMetric Incorporated, Lincoln, Rhode Island,
USA]) (13), demographic items, questions about resource use,
and a chronic condition checklist also were employed.
Data Collection: To identify an optimal set of questions
for inclusion in the COPD-PS questionnaire, a national cross-
sectional survey of patients receiving care from 4 pulmonary
specialists and 8 general practice sites was conducted during
an 8-week period in 2004. Selected clinical sites were required
to have experience performing spirometry following American
ThoracicSociety(ATS)standards(14,15).Approvalofthestudy
protocol was obtained by each site using a central Institutional
Review Board (Chesapeake Research Review, Inc.), and all pa-
tients provided written consent.
Patients aged 35 years and older with a previously sched-
uled ofﬁce visit were recruited for study participation. Patients
were excluded from the study for the following reasons: being
allergic to bronchodilators, having a condition contraindicating
study participation, participating in another clinical study, or
currently seeking care for an acute respiratory problem. Based
on a priori power calculations for logistic regression and sensi-
tivity/speciﬁcity analyses (16–18), approximately 100 patients
with COPD were sought.
Patients completed the development survey and physicians
recorded patient demographics and medical history. Spirometry
was performed before and 10 minutes after albuterol admin-
istration via metered-dose inhaler (90 µg, 2 puffs), according
to ATS standards current at the time of the study (14) using
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COPD-PSTM questionnaire
Conceptual
Domain Abbreviated Item Content
Dyspnea How much of the time short of breath?
Out of breath with activity
Short of breath at night
Frequency of shortness of breath in last year
Short of breath limits exercise
Short of breath under speciﬁc conditions
(e.g., lying down, getting dressed, climbing
stairs, heavy exercise, etc.)
Out of breath more than others of same age
Cough Frequency of cough in last year
Cough ﬁrst thing in the morning
Persistent cough that won’t go away
Cough that makes chest hurt
Coughing “attacks” during exercise
Cough that wakes at night
Need to cough to clear chest
Use of cough remedies
Frequency of nagging cough
Phlegm Frequency of coughing up “stuff,” such as mucus or
phlegm
Brought up phlegm or mucus ﬁrst thing in the
morning
Need to clear chest of “stuff” in morning
Colds/ bronchitis Get a lot of chest colds
Colds stay with me
Colds last for weeks, not days
Seem to catch a cold more easily than others
Frequent bouts with bronchitis
Get bronchitis at least once every winter
Chest Congestion/
Wheezing
Feels like something stuck in chest or lungs
Feeling of heaviness in chest
Chest congestion
Noisy breathing when sleeping
Noisy breathing, gurgling, rattling during day
Functional Impact Do less than used to because of breathing
problems
Breathing problems limit usual activities,
enjoyment of life
Difﬁculty performing work or other daily activities
because of
breathing problems
Breathing problems limit usual activities
Breathing problems kept from socializing
Felt frustrated by breathing problems
Breathing problems left too tired to do daily
activities
Breathing problems kept from getting as much
done
Breathing problems make it difﬁcult to focus
attention on other things
Personal
Characteristics
Affected by strong smells, fumes
Smoking history (current and past status,
pack-years)
Family history of lung disease
Exposure to secondhand smoke at home, work
Live with someone who smokes
Exposed to dust, gases, etc., at work
COPD-PS: COPD Population Screener.
predicted values from Morris et al. (19). For the purposes of this
study, AO was deﬁned based on GOLD guidelines (postbron-
chodilator forced expiratory volume in 1 second/forced vital
capacity [FEV1/FVC] < 70%) (3) as airway obstruction that is
not fully reversible. Patients with AO, identiﬁed by spirometry,
were further characterized as having mild AO or moderate-to-
very-severe AO.
Spirometry tracings were reviewed post hoc by an indepen-
dent pulmonary specialist auditor to evaluate adherence to ATS
standards for acceptability and reproducibility. Patients with
spirometry tracings meeting the strict ATS criteria were in-
cluded in the analysis. A random subsample of patients (20%)
completed the development survey (but not spirometry) again
2 weeks later to generate test-retest reliability estimates; survey
methods to optimize return rates were implemented (20).
Statistical Analysis: Analyses were performed using SAS
(Version 8.2 for Windows, SAS Institute Inc., Cary, NC, USA)
and STATA (version 8.0; StataCorp LP, College Station, TX,
USA).
Item selection: Based on spirometry results, patients were
categorizedas“NoAO”and“AO.”Point-biserialcorrelationsof
survey items with dichotomous AO diagnosis were generated.
Forward stepwise logistic regression models were used to test
blocks of items with similar content to identify the best predic-
tors for AO status within each unidimensional set. Items within
contentblocksthatmetthecriterionforsigniﬁcantmodelcontri-
bution(p <0.10)wereretainedforinclusioninasecondstageof
modeling to identify the best multidimensional set of items (this
signiﬁcance level was selected to ensure items with any possi-
ble contribution to prediction were identiﬁed for further study).
Items were evaluated as both continuous variables and as sets of
dichotomized response options to study the contribution of the
total item and speciﬁc response options.
Age and smoking variables (including pack-years, categori-
calsmokingstatus,andothervariablesregardingsmokingexpe-
rience) were also tested to identify optimal questions. Based on
overallmodelﬁtandsigniﬁcantcontributionofindividualitems,
a ﬁnal multivariate logistic model was constructed. Consistency
oftheseresultswasexaminedacrossspecialistandgeneralprac-
tice sites. The ﬁnal model was applied to the total study sample
(N = 697) to study consistency across different sample deﬁni-
tions,althoughtheaccuracyoftheAOoutcomeinthefullsample
cannot be conﬁrmed. To estimate the robustness of ﬁnal model
results, 1000 bootstrap samples were drawn with replacement
from the original audited sample and analyzed.
Scoringandscreeningaccuracy: Threescoringoptionsfor
combining item responses in the ﬁnal model were evaluated: 1)
total sum of item responses, 2) dichotomous variable for each
item,and3)weightedsumofitemresponses.Receiveroperating
characteristic (ROC) analyses (21) were conducted to evaluate
theCOPD-PSscoreinscreeningforAO.TheareaunderanROC
curve(AUC),oddsratios,sensitivityandspeciﬁcity,positiveand
negative predictive values, and percent correctly classiﬁed were
estimated for the continuous screener score and at each scoring
level or “cut-point.”
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was assessed with product-moment and intraclass (22, 23) cor-
relations between scores at study entry and 2-week follow-up.
Empirical validation: Clinician-working-group input as-
sured a degree of content validity by deﬁning conceptual do-
mains and speciﬁc content items based on clinical experience.
COPDisassociatedwithdecrementsinqualityoflife(3);hence,
convergent and discriminant validity was assessed by corre-
lating COPD-PS scores and results from the SF-12v2 Health
Survey. A series of known-groups construct validation analyses
were conducted to examine the COPD-PS mean score differ-
ences between groups differing in the construct being measured
(24). We hypothesized that patients with more respiratory prob-
lems would score signiﬁcantly higher on the COPD-PS than
those without for the categories of AO severity groups, site
type, physician-reported COPD status, self-reported COPD sta-
tus, work/school absenteeism due to breathing problems, self-
reported use of bronchodilators, and overnight hospitalization
for breathing problems. The ROC analyses for COPD-PS and
CAO diagnosis were completed to examine concurrent validity
of the COPD-PS screener.
RESULTS
Patient Characteristics: Of the 697 patients completing
both the development survey and spirometry, 445 (64%) and
252 (36%) were from general practice and specialist sites, re-
spectively. A total of 295 patients who had spirometry results
meeting strict ATS standards were included in the analytic sam-
ple(105[36%]fromgeneralpractice;190[64%]fromspecialist
sites). Table 2 presents patient characteristics by provider type.
The average patient age for the total sample was 62.1 ± 13.0
years (range 35–91 years). Approximately 40% of the sample
was male. Patients enrolled from specialist sites were older and
more likely to be male, white, and less likely to be Hispanic.
Approximately 38% of patients had AO based on spirometry
results, severity being mostly moderate-to-very severe (85%).
Prevalence of AO differed by site type—17% and 50% of pa-
tientsenrolledfromgeneralpracticesitesandspecialistsiteshad
AO, respectively (p < 0.0001). The mean pre- and postbron-
chodilator FEV1% predicted for patients with AO and without
AO is shown in Table 3. In the AO group, the postbronchodila-
tor mean FEV1% predicted was only slightly higher than the
prebronchodilatormeanFEV1%predicted,suggestingthesepa-
tients had poorly reversible airway obstruction.
QuestionnaireItemSelection: Responsestopotentialitems
for the COPD-PS questionnaire met basic criteria for Likert-
type questions. Item responses were well distributed, and most
items had a standard deviation (SD) of at least 1.0. Item-level
missing data were less than 3% for all items, except shortness
of breath with activity (8% missing). Correlations of the survey
items with AO diagnosis ranged from 0.00 to 0.38. In the ﬁrst
stage of logistic models, 23 items were signiﬁcant (p < 0.10)
in predicting AO status.
A series of stepwise logistic regression analyses with the
23 items revealed that a combination of two symptom- and
Table 2. Patient characteristics by provider type
Analytic General
Sample Practice Pulmonologist
(N = 295) (N = 105) (N = 190)
100% 36% 64%
Mean Age (SD) 62.1 (13.0) 58.2 (14.4)* 64.2 (11.6)*
Male (%) 40.0 32.4† 44.2†
Education (%)
Less than high school 13.3 17.4 11.1
High school 24.1 15.3† 28.9†
Beyond high school 62.6 67.4 60.0
Employment (%)
Full/part-time student 0.0 0.0 0.0
Working full/part-time 33.2 36.3 31.5
Retired/unemployed 49.3 42.2 53.3
Homemaker/other 17.5 21.6 15.2
Marital status: married (%) 63.0 54.8† 67.6†
Ethnic background (%)
Black/African American 6.9 10.6 4.8
White 82.5 63.5* 93.1*
Asian/Paciﬁc Islander 0.7 1.9 0.0
American Indian/Alaskan 0.7 1.0 0.5
Native
Hispanic/Spanish/Latino 9.3 23.1* 1.6*
Smoking status (%)
Current smoker 16.4 21.1 13.7
Never smoker 35.5 49.5* 27.9*
Former smoker 48.1 29.1* 58.4*
Chronic conditions
(self-report, %)
Arthritis 48.8 48.6 49.0
Hypertension 46.9 53.3 43.4
Rhinitis or sinusitis 39.7 43.3 37.8
Asthma 41.0 34.6 44.4
COPD 38.2 20.2* 48.2*
Other lung problems 28.3 8.8* 39.2*
Clinical depression 17.7 21.0 15.9
Diabetes 19.7 22.1 18.4
Cancer, except skin cancer 11.5 10.5 12.1
Congestive heart failure 11.9 12.4 11.6
Chronic conditions
(clinician-report, %)
Arthritis 43.1 45.7 41.6
Hypertension 42.7 51.4† 37.9†
Rhinitis or sinusitis 42.2 46.7 40.0
Asthma 36.4 32.7 38.5
COPD 39.1 21.0* 49.2*
Other lung problems 25.5 7.7* 35.3*
Clinical depression 17.4 21.9 14.8
Diabetes 16.7 21.9 13.8
Cancer, except skin cancer 9.5 10.5 9.0
Congestive heart failure 10.5 10.5 10.6
Effects of breathing
problems (%)
Missed 1+ days work/school 10.5 5.7 13.6
in past 4 weeks
Hospitalized overnight 7.0 2.9† 9.3†
in past 3 months
AO diagnosis: 38.4 17.1* 50.3*
FEV1/FVC < 70% (%)
SD: standard deviation; COPD: chronic obstructive pulmonary disease;
FEV1:f orced expiratory volume in 1 second; FVC: forced vital capacity.
∗p < 0.01; †p < 0.05.
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Pre-BD Mean Post-BD Mean
FEV1% FEV1%
N (%) Reversibility predicted (SD) predicted (SD)
No AO:
Pre-BD FEV1/FVC ≥ 70% 169 (58%) — 91.1 (18.4) 93.0 (18.7)
Post-BD FEV1/FVC ≥ 70%
Pre-BD FEV1/FVC < 70% 12 (4%) 41.7% 58.8 (31.3) 67.4 (32.1)
Post-BD FEV1/FVC ≥ 70%
AO:
Pre-BD FEV1/FVC < 70% 113 (38%) 10.6% 56.2 (24.2) 58.8 (26.1)
Post-BD FEV1/FVC < 70%
Reversibility: ≥ 200 mL improvement and ≥ 12% improvement of baseline FEV1. SD: standard deviation; FEV1:
forced expiratory volume in 1 second; BD: bronchodilator; COPD: chronic obstructive pulmonary disease; FVC:
forced vital capacity.
onefunctioning-baseditemsbestdiscriminatedbetweenpatients
with and without AO: shortness of breath frequency, production
of sputum/phlegm frequency, and functional limitations due to
breathing problems. Also the interaction of dyspnea and cough
items was signiﬁcantly predictive of AO. The same three vari-
ables performed the best in regression models with the total
sample as well. Two items were signiﬁcantly associated with
AO,b ut in the negative direction. Awake at night with breathing
problemsandneedtoclearchestinthemorningpredictedalack
of AO but added little to the overall model ﬁt. As such, only
items with a positive association with AO were retained for the
COPD-PS questionnaire.
Patient characteristics were added to the logistic model; age
and smoking history improved AO prediction. Three versions
of smoking variables were assessed: pack-years, categorical
smoking status (i.e., current, former, never-smoker) and a single
item regarding lifetime consumption of at least 100 cigarettes.
The simple, single-item measure presented the best trade-off
Table 4. Summary of logistic regression results
Analytic Sample (N = 294)
Item Response
Item-Response
Weights
Item
OR
(95% CI)
Response
Options
ORs
OR,
CIs
During the past 4 weeks, how much of the time
did you feel short of breath?
None of the time 0 1.07 — —
A little of the time 0 (0.75, 1.53) 1.27 0.38, 4.28
Some of the time 1 0.88 0.26, 2.98
Most of the time 2 1.13 0.30, 4.24
All of the time 2 0.40 0.06, 2.63
Do you ever cough up any “stuff,” such as
mucus or phlegm?
No, never 0 0.91 — —
Occas. colds 0 (0.72, 1.15) 1.49 0.49, 4.56
Fewd aysamonth 1 1.84 0.54, 6.22
Most days a week 1 1.48 0.43, 5.04
Yes, every day 2 1.85 0.57, 6.05
Please select the answer that best describes
youi nthe past 12 months. I do less than I
used to because of my breathing problems.
Strongly disagree 0 1.64∗ ——
Disagree 0 (1.25, 2.16) 0.77 0.23, 2.58
Unsure 0 0.89 0.22. 3.54
Agree 1 2.28 0.80, 6.54
Strongly agree 2 6.78† 1.96, 23.47
Have you smoked at least 100 cigarettes in
your ENTIRE LIFE?
No 0 5.80∗ ——
Yes2 (2.81, 11.96) 5.80∗ 2.68, 12.58
How old are you? Aged 35 to 49 y 0 2.68∗ ——
Aged 50 to 59 y 1 (1.92, 3.74) 2.85 0.78, 10.41
Aged 60 to 69 y 2 6.80† 1.98, 23.35
Aged 70+ y2 23.80∗ 6.84, 82.83
Overall model ﬁt: LR test: 122.13, 16 df, p < 0.0001
OR: odds ratio; CI: conﬁdence interval; Occas.: Occasionally; LR: likelihood ratio; df: degrees of freedom.
∗p < 0.001; †p < 0.01.
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Patient Characteristics Mean Score (SD)
Total population 5.04 (2.58)
Non-White 3.35 (2.61)
White 5.43 (2.41)
Male 5.36 (2.50)
Female 4.84 (2.61)
No AO 3.99 (2.35)
AO (all severity levels) 6.76 (1.94)
Mild AO (GOLD stage I) 6.33 (2.29)
Moderate/very severe AO 6.83 (1.89)
(GOLD stage II+)
General practice site 3.99 (2.70)
Specialist site 5.63 (2.31)
COPD-PS: COPD Population Screener; SD: standard
deviation; AO: Fixed airﬂow obstruction; COPD: chronic
obstructive pulmonary disease; GOLD: Global Initiative for
Chronic Obstructive Lung Disease.
betweenexplanatorypowerandeaseofadministration.Second-
hand smoke exposure was evaluated regardless of individual
smokingstatusandwasnearlyasigniﬁcantpredictor(p <0.08),
but did not improve overall model ﬁt. The ﬁnal logistic model
with 5 variables produced signiﬁcant overall ﬁt (likelihood ratio
χ2 = 122.13, p < 0.0001; pseudo R2 = 0.47).
Table 4 presents results for the ﬁnal model. The results in
the ﬁnal analytic sample, conﬁrmed to have met ATS standards
for spirometry performance were compared with the full study
sample results (likelihood ratio χ2 = 113.50, p < 0.0001) and
were found to be consistent. Interactions of provider type with
items and item-response weights were not statistically signif-
icant, indicating that items were not differentially predictive
across provider type, and scoring weights functioned equally
for general practice and specialist sites. The mean, median, and
5th and 95th percentiles for the 1000 bootstrap sample regres-
sion model results revealed little variation in model coefﬁcients
from the analytic sample results.
Scoring and Screening Accuracy: Of the 3 techniques used
to evaluate scores, the weighted-sum technique produced the
best results for discriminating between patients with and with-
out AO. Each item response was assigned a value of 0, 1,
or 2, depending on the relative contribution of the response
to identifying AO, and response values were summed across
the items to produce a scale score ranging from 0 (unlikely to
have AO) to 10 (likely to have AO). Table 5 presents COPD-
PS mean scores by selected patient characteristics. Figure 1
presents the ROC curve associated with the ﬁnal COPD-PS
score. The AUC corresponding to a model with 5 individual
screener items was 0.86, and for the total score it was 0.81.
Based on sensitivity (59.6%) and speciﬁcity (83.2%) for the
total score, the positive likelihood ratio (LR+) for the survey
was 3.56.
Table 6 summarizes the performance of the COPD-PS score
in identifying patients with AO across multiple score levels.
In these analyses, screener scores were dichotomized to al-
low an analysis of cut-point performance relative to AO di-
agnosis. Lower cut-point scores were associated with higher
sensitivity and lower speciﬁcity, while higher scores produced
lower sensitivity and higher speciﬁcity. A cut-point in the range
of 5 to 6 provided a good trade-off between sensitivity and
speciﬁcity, as well as high correct classiﬁcation rates for AO
diagnosis.
Figure 1. ROC curve: COPD-PSTM score and AO diagnosis. ROC: receiver operating characteristic; AUC: area under the curve; COPD-PS:
COPD Population Screener; COPD: chronic obstructive pulmonary disease.
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Positive Negative Percent (%) Area
Cut-Point
Score
Odds
Ratio
Sensitivity
(%)
Speciﬁcity
(%)
Predictive
Value (%)
Predictive
Value (%)
Correctly
Classiﬁed
Under
ROC Curve
≥ 4 11.10 93.6 43.3 50.3 91.7 62.4 0.68
5 8.34 84.4 60.7 56.8 86.4 69.7 0.73
6 7.69 73.4 73.6 63.0 81.9 73.5 0.74
7 7.29 59.6 83.2 68.4 77.1 74.2 0.71
8 7.92 40.4 92.1 75.9 71.6 72.5 0.66
9 8.75 20.2 97.2 81.5 66.5 67.9 0.59
Continuous
Score 1.72 59.6 83.2 68.4 77.1 74.2 0.81
COPD-PS: COPD Population Screener; COPD: chronic obstructive pulmonary disease; AO: ﬁxed airﬂow obstruction; ROC:
receiver operating characteristic.
Reliability: Table 7 presents mean scores for the analytic
sample and by AO diagnosis for a random subsample of 57 pa-
tients completing the study surveys at entry and 2-week follow-
up. For the analytic sample, the test-retest Pearson’s product-
moment correlation was 0.91 and the intraclass estimate was
0.91. Test-retest reliability estimates were slightly lower within
each diagnostic group (AO and no AO), but the sample sizes
may have been too small for accurate estimation.
Empirical Validation: Convergent and discriminant valid-
ity results are presented in Table 8, where scales are arranged
in order from those designed to assess more physical aspects of
health to those measuring mental health (higher SF-12v2 scores
represent better health while higher COPD-PS scores represent
higher likelihood of having AO). COPD-PS scores had higher
correlations with scales designed to measure physical function-
ing, role limitations due to physical health, and general health
status.LowercorrelationswerefoundbetweenCOPD-PSscores
and scales designed to assess well-being domains, such as men-
tal health.
Table 9 presents results of known-groups validity analyses.
COPD-PS mean scores were signiﬁcantly higher for patients
with AO than without (6.8 vs 4.0, p < 0.0001). Scores for pa-
tients with mild AO were signiﬁcantly higher than for patients
with no AO (p < 0.01), but the difference between AO severity
groups was not statistically signiﬁcant. Patient- and physician-
reported COPD also produced signiﬁcantly higher mean scores.
Bronchodilator use and overnight hospitalization were associ-
ated with signiﬁcantly higher COPD-PS scores. Results from
concurrent validity analyses demonstrated that the COPD-PS
scorepredictedphysician-reportedCOPDaswellasspirometry-
based diagnosis (model likelihood ratio χ2 = 148.57, p <
0.0001). AUC for the analytic sample was 0.88, for the continu-
ous score sensitivity was 66% and speciﬁcity was 89%. Eighty
percent of patients were correctly classiﬁed.
DISCUSSION
Simple tools are needed to help identify persons who
have COPD. A brief, easy-to-complete questionnaire based on
patient-reported information can serve as a ﬁrst-level screen. A
screeningassessmentmayhelpcliniciansidentifypatientsatrisk
for COPD, prompting clinical review and spirometric assess-
ment, which are necessary to conﬁrm a diagnosis. Furthermore,
dissemination of a COPD screener in the general population
might encourage individuals with pulmonary symptoms to visit
their physician. This study represents the development and ini-
tial validation of a simple, reliable, self-scored COPD screening
questionnaire. Three COPD-related items (breathlessness, pro-
ductive cough, and activity limitation), a smoking history item
(100ormorecigarettessmokedinlifetime),andanageitemwere
used to construct the COPD-PS questionnaire. A weighted-sum
score of these items resulted in a questionnaire that discrimi-
natedbetweenpatientswithandwithoutAO,andcouldbeeasily
adapted to an electronic format for simple scoring.
The hallmark symptoms of COPD are dyspnea, chronic
cough, chronic sputum production, and a history of exposure
Table 7. Test-retest reliability of COPD-PSTM scores
Time 1
Mean (SD)
Time 2
Mean (SD)
Pearson’s
Test-Retest
Reliability
Intraclass
Coefﬁcient
Reliability
Total Sample (N = 57) 5.42 (2.5) 5.42 (2.4) 0.91 0.91
No AO (N = 36) 4.36 (2.2) 4.56 (2.4) 0.89 0.88
AO (N = 21) 7.24 (1.8) 6.90 (1.8) 0.88 0.86
COPD-PS: COPD Population Screener; SD: standard deviation; COPD: chronic obstructive
pulmonary disease; AO: ﬁxed airﬂow obstruction.
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Correlation
With COPD-PS
PCS-12 −0.47
Physical Functioning −0.50
Role–Physical −0.50
Bodily Pain −0.12
General Health −0.39
Vitality −0.28
Social Functioning −0.23
Role–Emotional −0.23
Mental Health −0.10
MCS-12 −0.06
COPD-PS: COPD Population Screener; SF-12v2 Health Survey:
12-item, short-form, general-health-status assessment; PCS-12:
physical health summary measures of the SF-12 Health Survey;
MCS-12: mental health summary measures of the SF-12 Health
Survey.
to risk factors, such as smoking (3). The COPD-PS identiﬁes
these symptoms and risks, as well as considers age as a screen-
ing factor for COPD. The COPD-PS is unique in that it is a
self-administered, self-scored questionnaire that utilizes a scor-
ing system to predict spirometry-based diagnosis of the disease.
Individual COPD-PS items were not all signiﬁcant predictors of
COPD in a multivariate logistic model, but their combination
produced a well-ﬁtting model and a ﬁnal score that performed
well in tests of sensitivity and speciﬁcity. Scores met generally
accepted standards for individual-level reliability (24), suggest-
ing that they are not only appropriate for group-level inferences
but also can be applied reliably at the individual level.
The clinician working group tested several different versions
ofitemsthatassessedconceptstypicallyassociatedwithCOPD.
This allowed identiﬁcation of questions that could be easily un-
derstood and completed by patients across a range of literacy
skills.Someparticularitemwordingshadastrongerrelationship
to COPD than others. Surprisingly, several concepts identiﬁed
Table 9. Comparison of COPD-PSTM mean scores across patient variables
AO Comparison Variable N Mean SD T
COPD diagnosis
No AO: FEV1/FVC > 70% 178 4.0 2.3
AO: FEV1/FVC < 70% 109 6.8 1.9 −10.79*
AO severity
No AO 178 4.0 2.3
Mild AO: FEV1 > 80% predicted 15 6.3 2.3 −3.70†
Moderate/very severe AO: FEV1 <
80% predicted
94 6.8 1.9 −10.79∗1 −0.922
Practice type
General practice 103 4.0 2.7
Pulmonologist 185 5.6 2.3 −5.43∗
Self-report
No COPD 175 3.8 2.2
Have COPD 111 7.0 1.7 −13.93∗
Physician-report
No COPD 175 3.7 2.1
Have COPD 112 7.1 1.7 −14.88∗
Use of bronchodilators
No use in past 4 weeks 101 3.3 2.2
Use in past 4 weeks 186 6.0 2.3 −9.71∗
Work/school loss in past 4 weeks
Did not miss due to breathing
problems
116 3.9 2.4
Missed 1+ days due to breathing
problems
17 4.8 2.9 −1.36
Hospitalization in past 3 months
No overnight hospitalization due to
breathing problems
261 4.9 2.6
1+ overnight hospitalizations due to
breathing problems
19 6.5 2.7 −2.65†
COPD-PS: COPD Population Screener; COPD: chronic obstructive pulmonary disease; AO: ﬁxed
airﬂow obstruction; SD: standard deviation; FEV1:f orced expiratory volume in 1 second; FVC:
forced vital capacity.
∗p < 0.001; †p < 0.01.
1 Moderate/very severe AO vs No AO.
2 Moderate/very severe AO vs Mild AO.
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bronchitis, and chest congestion or wheezing—did not serve
to distinguish between patients with AO and those without AO.
Although these are likely important aspects of the disease, self-
reporting of cough, colds, and chest congestion did not improve
thedifferentiationbetweenAOandnoAOwhenbreathlessness,
phlegm, functional limitations, smoking status, and age were
considered. This may relate to the similarity shared by several
pulmonary conditions for these nondistinguishing symptoms.
The group studied the contribution of smoking status, mea-
sured in multiple ways, to prediction of COPD. Each smoking
variable performed similarly in discriminating between patients
with and without AO when tested in combination with other
screening items. In our attempt to develop an easy-to-complete
questionnaire that did not require complicated calculations, the
combination of explanatory power and ease of administration
resulted in the selection of a single-item smoking measure for
theCOPD-PS.Otherstate(25,26)andnational(27,28)surveys
have used a similar “smoked at least 100 cigarettes” item. Its
inclusion in the COPD-PS allows for comparison of smoking
rates with nationally published ﬁgures.
We demonstrated validity of the COPD-PS through multiple
concurrent and construct approaches. Higher COPD-PS scores
cangenerallybeinterpretedasindicatinganincreasedlikelihood
of AO. Lower cut-point levels were associated with greater de-
tectionofpatientswithAO(highersensitivity)butalsoincluded
somepatientsnothavingAO(lowspeciﬁcity).Theoppositewas
true at higher scores. Thus, selection of a particular cut-point
value can be adapted for a particular application. For example,
ifthegoalistoidentifyasmanyindividualswithpotentialCOPD
as possible, with less concern for including those who may not
have the disease, a score corresponding to high sensitivity and
lower speciﬁcity can be considered. This could result in signif-
icant health care resource expenditure. On the other hand, if an
application requires a higher level of certainty that all identiﬁed
individualsdohaveCOPD,ascoreassociatedwithhigherspeci-
ﬁcity is desirable. As such, the optimal scoring utilized should
be adapted to the situation and with regards to the health care
utilization implication of this decision.
In contrast to this self-report questionnaire, some earlier
COPD screening tools require clinical information from the
medical record (29, 30) or previous report of a physician di-
agnosis of COPD (31) for scoring. Others require interviewer
administration,includecomplicatedcalculationsorskippatterns
that make it difﬁcult to self-administer, or are intended only for
a particular population, such as current or former smokers (32).
The value of self-report surveys relative to spirometry has been
demonstratedforCOPDcaseﬁnding(32–34).vanSchaycketal.
identiﬁed an optimal combination of items from NHANES-III
for distinguishing between those with and without COPD, but
because that study did not include reversibility testing, it is un-
clear how well results will generalize to COPD diagnoses based
on GOLD deﬁnitions of the disease (35).
Price et al. generated an 8-item COPD questionnaire devel-
opedinpatientswithapositivesmokinghistoryandnoprevious
respiratorydiagnosisidentiﬁedthrough2primarycarephysician
ofﬁcesites(UnitedKingdomandUnitedStates)(32).Thisques-
tionnaire included items related to age group, body mass index,
pack-year history, and symptoms and featured a scoring system
suitable for use in primary care settings. Scores on this case-
ﬁnding tool were separated into 3 “zones,” indicating increased,
unchanged, and decreased likelihood of COPD compared with
thetotalstudypopulation(whichasawholehasanincreasedrisk
of COPD due to inclusion criteria); patients with a higher likeli-
hood should be referred for spirometry (36). Although some of
theitemsaresimilartothoseoftheCOPD-PS,itsderivationsug-
gests that this instrument is better suited for use in a physician’s
ofﬁce in higher risk populations.
Similarly, Freeman et al. identiﬁed 4 features (age, cough,
dyspnea, and wheezing) that identiﬁed patients with COPD
among a primary care population with a positive smoking
history, history of use of respiratory medications, or a his-
tory of asthma (33). Calverley et al. developed a population-
based screening questionnaire for COPD retrospectively, using
NHANES III data (12). The COPD-PS differs from these other
instrumentsbecauseitcanbeusedinabroadergroupofindivid-
uals, regardless of smoking history or known presence of res-
piratory problems. Although other instruments include age and
symptom-based items, the COPD-PS also contains a disease-
impact item, which allows the patient to describe activity limi-
tations due to breathing problems.
A limitation of this study includes the deﬁnition for COPD.
Although the screener identiﬁed patients with AO and not nec-
essarily COPD, it does identify patients for whom spirometry
would be indicated and in whom additional clinical evaluation
would be required to conﬁrm a COPD diagnosis. Furthermore,
theimportantcontributionofthesmokingitem,thelimitedbron-
choreversibility of patients with AO, and the high correlation
with physician-reported COPD strongly support that cases with
AO identiﬁed had a COPD diagnosis. In fact there was only fair
concordance between subject reported or clinician diagnosed
COPD and conﬁrmed COPD; one in ﬁve spirometry-identiﬁed
COPD patients did not report having a previous COPD history
by either self-report or clinician diagnosis.
An additional limitation reﬂects the source of the analytic
sample studied. Patients were recruited from a clinical setting
to allow postbronchodilator spirometric assessment. In addition
to patients from specialist sites, patients from general practice
sites were enrolled, with the intention of accessing individuals
who were not already seeing a pulmonary specialist for respira-
torysymptoms.Similarly,recruitedpatientswerebeingseenfor
routine, previously scheduled, ofﬁce visits to maximize gener-
alizability.ItisimportanttorealizethattheprevalenceofCOPD
washigherinthecohortstudiedthanwouldbeanticipatedingen-
eral population samples, which may have increased the positive
predictive value of the COPD-PS. Validation in an independent
general population sample is required to deﬁne the operating
characteristics in this setting.
Patients were visiting their physician for other medical prob-
lems, which might confound the diagnosis of COPD. An addi-
tional limitation was the low rate of adherence to ATS standards
for spirometry testing. More than half of the tests carried out in
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or acceptability standards for 3 tracings, according to external
review. However, even in 2 of the 4 specialist sites, there were
many tracings that were excluded.
Despite this, results of analysis in the analytic sample were
similar to the results for the entire study population. Impor-
tantly, the lack of adequate spirometry performance in a ma-
jority of subjects supports the need for aggressive training in
spirometric testing if a screening instrument such as the COPD-
PS is to be widely employed. Previous investigators have con-
ﬁrmed that a majority of maneuvers performed in the primary
care setting without access to training failed to meet repro-
ducibility criteria (37). This group and others have conﬁrmed
improvement in spirometry quality with limited training (38).
Using primary care physicians to identify early COPD with
spirometry will require ensuring that spirometry is properly
performed (6).
Validation studies are needed to conﬁrm the performance
of the COPD-PS questionnaire among individuals in commu-
nity settings. Future studies may choose to evaluate whether
additional item content can improve the performance of a brief
COPD screener. Cognitive interviews or focus groups with pa-
tients or individuals from the general population may provide
additional information about the acceptability and readability
of the COPD-PSquestions. Although a secondhand smoke item
approachedstatisticalsigniﬁcanceinouranalyticsample,future
studies evaluating this item in nonsmokers may be of interest.
The developmental survey did not include self-report items for
calculating body mass index. Items that separate asthma and
COPD could also be evaluated. The COPD-PS can be evaluated
for its utility as a ﬁrst-stage screener in various settings, such as
population screening, clinical practice, disease management, or
population-based research.
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Appendix A. Item content of variables tested for inclusion in the COPD-PSTM survey
Conceptual Domain Item Content
Dyspnea During the past 4 weeks, how much of the time did you feel short of breath?
Do you get out of breath with activity?
On average, breathing problems usually keep me awake at night...(frequency)
Over the last year, I have had shortness of breath:
During the past 4 weeks, how often did breathing problems limit your ability to exercise as much as you would like?
In the past 4 weeks, how often have you felt short of breath under the following conditions? (When lying down ﬂat;
When sitting or resting; Getting dressed; When walking less than one block; Bending over; When climbing one
ﬂight of stairs; With heavy exercise or manual work (running, cycling, swimming fast))
Do you get out of breath more easily than others your age?
Cough Over the last year, I have coughed:...(frequency)
In the past 4 weeks, how often have you had any of the following? (Coughing ﬁrst thing in the morning; A cough
that just won’t go away; A cough that makes your chest hurt; Coughing “attacks” when you exercise; A cough that
wakesy ou up at night; A need to cough to clear your chest)
How often in the past 4 weeks have you had a nagging cough?
Phlegm Do you ever cough up any ‘stuff’, such as mucus or phlegm?
How often in the past 12 months have you brought up phlegm or mucus ﬁrst thing in the morning?
Please select the answer that best describes you in the past 12 months. I have to clear my chest of stuff when I
wake up in the morning.
Colds/ bronchitis Please select the answer that best describes you in the past 12 months. (I get a lot of chest colds; When I get a
cold it really stays with me; My colds last for weeks rather than days; I seem to catch a cold more easily than
other people do; I get bronchitis at least once every winter; I have frequent bouts with bronchitis)
Chest Congestion/ Wheezing In the past 4 weeks, how often have you had any of the following? (A feeling like something might be “stuck” in your
chest or lungs; A feeling of heaviness in chest; Noisy breathing when you sleep; Chest congestion; Noisy
breathing during the day (gurgling, bubbling, rattling)
Functional Impact I do less than I used to because of my breathing problems.
In the past 4 weeks, how much did breathing problems limit your usual activities or enjoyment of everyday life?
In the past 4 weeks, how much of the time did you have difﬁculty in performing work or other daily activities
because of breathing problems?
In the past 4 weeks, how often: (did breathing problems limit you in performing your usual work activities, including
housework, work, school or social activities; did breathing problems keep you from socializing; did you feel fed up
or frustrated because of breathing problems; did breathing problems leave you too tired to do work or daily
activities; did breathing problems keep you from getting as much done at work or at home; did breathing
problems make it difﬁcult for you to focus your attention on other things?)
Personal Characteristics Do you ﬁnd that certain strong smells such as exhaust fumes, cigarette smoke or paint fumes affect you: (extent of
effect)
Smoking history (Current and past status, pack-years)
Do you have a family history of emphysema or chronic lung problems?
Have you been exposed to tobacco or other kinds of second-hand smoke at home or work for extended periods of
time?
Do you live with someone who smokes?
Have you been exposed to dust, gases, or dirty air at work?
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